XML 114 R85.htm IDEA: XBRL DOCUMENT v3.25.4
Information about Component of Consolidated Statements of Comprehensive Income - Schedule of Other Income or Expenses, Net (Details) - USD ($)
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Schedule of Other Income or Expenses, Net [Abstract]      
Loss from subsidiary’s guarantee recognition $ (61,681,998)
Gain on bargain purchase 1,473,482 1,032,327
Remeasurement to fair value of pre-existing interest in an acquiree (1,666,680)
Net result from commercialization of agricultural products (1,890,110) (3,560,703) 174,122
Result of intangible assets 7,649,848 [1] 125,464
Others (473,758) 1,825,111 881,177
Total $ (56,589,216) $ (703,265) $ 1,055,299
[1] On March 28, 2025, BIOX, a former subsidiary, agreed to transfer all rights, licenses, and materials containing or pertaining to the Soy ANF trait and pay $750,000 to a Arcadia Biosciences Inc in exchange for (i) RG and OX Wheat Patents and RS exclusive rights; (ii) the cancellation of all Royalty Payments, which included 25% of the Net Wheat Technology Licensing Revenues and 6% of the Net HB4 Soybean Revenues up to $10 million; and (iii) the release from any Performance Benchmark Obligations related to the RG, OX, and RS Varieties which amounted to $8.1 million. This transaction resulted in the accounting of a gain from the exchange of intangible assets amounting to $7.5 million.